RECRUITINGINTERVENTIONAL
Prevention of NAFLD and CVD Through Lifestyle Intervention
Cardiovascular Diseases (CVD) and Nonalcoholic Fatty Liver Diseases (NAFLD) Among Gallstone and Cholecystectomy Patients and the Impact of a Novel Diet and Muscle Training Program
About This Trial
Prevention of non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) through lifestyle intervention (MAUCO+) is a clinical trial that aims to improve sarcopenia, aerobic capacity, body composition, and lipid profile, insulin resistance, cardiovascular risk, NAFLD, and maintain a healthier lifestyle. Through the implementation of physical activity and nutritional programs.
Who May Be Eligible (Plain English)
Who May Qualify:
- With and without gallstones disease
- With various degrees of NAFLD (none too severe)
Who Should NOT Join This Trial:
- Any significant comorbidity or physical limitation to undergo resistance exercise program
- Use of medications that alter muscle mass (e.g., corticosteroids)
- History of hepatitis B or C
- Use of hepatotoxic drugs
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* With and without gallstones disease
* With various degrees of NAFLD (none too severe)
Exclusion Criteria:
* Any significant comorbidity or physical limitation to undergo resistance exercise program
* Use of medications that alter muscle mass (e.g., corticosteroids)
* History of hepatitis B or C
* Use of hepatotoxic drugs
Treatments Being Tested
OTHER
Physical exercise and dietary intervention for NAFLD
Investigators will assess the efficiency of the intervention by measuring adherence to physical exercise and nutritional diet.
Locations (1)
Centro MAUCO+
Molina, Maule Region, Chile